2014年11月25日讯 /生物谷BIOON/ --彭博社周一援引知情人士消息，德国制药巨头拜耳（Bayer AG）正在探索出售其糖尿病设备单元，瑞士瑞信银行(Credit Suisse)正在为拜耳就糖尿病设备单元的潜在出售提供咨询，售价可能在10-20亿欧元（约合12.4-24.9亿美元）。报道称，私募股权公司如Cinven、EQT Partners AB和Triton Advisers可能会考虑竞标。
拜耳的糖尿病设备单元在2013年的销售额超过7亿欧元，产品包括血糖仪，该业务是拜耳医疗保健单元的一部分。彭博社还报道称，拜耳有意收购动物保健公司Zoetis。Zoetis原为辉瑞（Pfizer）旗下动物保健部门，2012年辉瑞将动物保健业务分拆独立成一家公司Zoetis，其中文名为“硕腾”。Zoetis是全球动物保健药和疫苗行业最大的公司之一，其直接竞争对手包括默克(MRK)、赛诺菲(SNY)、美国礼来(LLY)等大型制药公司旗下的动物保健部门。
彭博社报道，拜耳正在寻求从拆分塑料单元上市及出售糖尿病设备单元等途径来筹集资金收购Zoetis。今年10月，拜耳表示，其材料业务（MaterialScience）将在2016年中期作为一家独立的公司上市，从而使拜耳成为一家纯粹的生命科学公司，专注于医疗保健和作物科学。拜耳的定位是使自己成为一家在人类，动物和植物健康领域全球领先的公司。
医疗保健巨头默沙东（Merck & Co）在今年10月表示，已完成将其消费保健业务以142亿美元出售给拜耳，主要包括治疗感冒、过敏、鼻炎和流感、皮肤病产品及胃肠道类产品。而拜耳同时将获得默沙东现有的非处方药业务。
英文原文：Bloomberg: Bayer Explores Sale Of Diabetes Device Unit
German conglomerate Bayer AG (BAYZF.PK,BAYRY.PK,BYR.L) is exploring a sale of its diabetes device unit, Bloomberg reported Monday, citing people with knowledge of the matter.
According to the Bloomberg report, Credit Suisse Group AG is advising Bayer on a potential sale of the unit, which could fetch between 1 billion euros and 2 billion euros, or $1.24 billion to $2.49 billion. Private equity firms like Cinven Ltd., EQT Partners AB and Triton Advisers Ltd. may reportedly consider bidding for the unit.
Bayer's diabetes devices unit makes products, including the blood-glucose meter Contour, which had annual sales of more than 700 million euros in 2013. The business is part of the company's health-care unit.
Bloomberg also reported that Bayer is interested in acquiring animal health company Zoetis Inc. (ZTS: Quote), a former unit of Pfizer Inc. (PFE). The company is seeking to raise money for the acquisition of Zoetis from the listing of its plastics unit and the sale of its diabetes devices unit.
In October, Bayer said its MaterialScience business will be floated on the stock market as a separate company latest by mid-2016, thus making Bayer a pure life science company that will focus on Healthcare and CropScience. Citing its strong operating performance and including the consumer care business acquired from Merck & Co., Inc. Bayer raised its financial guidance for 2014 at that time.
Bayer had earlier said its plan to divest plastics business and focus entirely on life science, that would position itself as a world-leading company in the field of human, animal and plant health.
Healthcare giant Merck & Co., Inc. (MRK) said in early October that it completed the sale of its consumer care business to Bayer, including the global trademark and prescription rights for Claritintm and Afrintm, for $14.2 billion.
Bayer gets Merck's existing over-the-counter drug business with about 2,250 employees. The unit's business primarily includes leading brands such as Claritin for allergy, Coppertone for sun care, Dr. Scholl's for foot health, and Afrin for colds.
BAYZF closed Monday's trading at $147.75, up $4.35 or 3.03 percent on a volume of 747 shares.
In Frankfurt, Bayer's shares closed Monday's trading at 117.45 euros, down 0.55 euros or 0.47 percent on a volume of 2.42 million shares.